Health Economics and Outcomes Research (HEOR) Services Market Assessment, By Services [Economic Evaluation, Real World Data Analysis and Information, Clinical Outcome, Market Access Solution and Reimbursement, Others], By Service Provider [Contract Resear

Global health economics and outcomes research (HEOR) services market is projected to witness a CAGR of 12.15% during the forecast period 2025-2032, growing from USD 1.46 billion in 2024 to USD 3.66 billion in 2032. The market’s growth is bolstered by the increasing requirements for outcome data and real-world evidence for reimbursement, increasing investments in research and development activities by leading research and government organizations, and rising utilization of HEOR services by pharmaceutical and biotech companies. Additionally, the increasing number of clinical trials is also driving the market's growth. Moreover, the rising number of clinical trials in different regions across the globe is also bolstering the market’s demand. As of 2nd May 2025, 536,389 studies are registered at ClinicalTrials.gov, the publicly available registry and results database, which is run by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).

The market’s growth is also bolstered by the increasing pressure to control healthcare costs while ensuring that the patient population is provided with high-quality care, along with the rising importance of evidence-based decision making in reimbursement and clinical frameworks. Furthermore, the growing focus on value-based care, optimization of reimbursement processes, and transparency in drug pricing are also propelling the market’s expansion.

Technological Advancements Drive Market Demand

The market’s growth is supported by the increasing focus on novel launches to provide high-quality services to the healthcare and biopharmaceutical industries. For instance, in November 2023, Stratevi LLC launched StrateFlow, a custom-built software to aid HEOR, medical, and access teams in enabling stakeholder alignment and project management while juggling priorities. The platform’s three core modules include Project Planner, Evidence Hub, and HTA Optimizer, which streamline project management, centralize evidence and value communication, and facilitate efficient planning and tracking of HTA submissions across the globe. As pharmaceutical companies increasingly rely on digital solutions to manage increasing data complexities and regulatory demands, platforms such as StrateFlow are expanding the capabilities and reach of HEOR services. This innovation not only improves internal processes but also strengthens the ability of HEOR teams to demonstrate product value, ultimately fueling the growth of the market.

Strategic Alliances Support Market Expansion

Strategic alliances, including partnerships, mergers, and acquisitions, allow companies to combine their expertise and resources, aiding them in expanding their customer base and improving their service portfolios. Alliances also support innovation by ensuring the integration of resources and skills, streamlining complex processes such as regulatory compliance and drug development for pharmaceutical and biotech companies.

In April 2024, PharmAlliance, Inc. acquired Complete Health Economics Outcomes Research Solutions (CHEORS), allowing the former to expand its market presence and ensure the launch and commercialization of new products and services. The latter holds expertise in health technology assessment (HTA), economic modeling, and evidence synthesis. Such partnerships accelerate the adoption of HEOR services by providing clients with data-driven insights, facilitating rapid and efficient decision-making.

Consultancy Accounts for Significant Share of the Market

The segment's dominance can be attributed to the role of consultancies in providing strategic guidance and expertise to healthcare, biotech, and pharmaceutical companies in navigating complex reimbursement policies and regulatory environments. These organizations offer customized solutions in a wide range of domains, including economic modeling, pricing, market access, and real-world evidence, which are essential for demonstrating product value to healthcare professionals, policy regulators, and payers.

Furthermore, the rising collaborations between consultancies and market vendors are also supporting the segment’s growth, providing lucrative growth opportunities for the market. For instance, in August 2024, ADVI Health, LLC acquired Partnership for Health Analytic Research, LLC, a global HEOR consultancy known for providing data-driven and high-impact insights to biopharmaceutical clients and sponsors. Such acquisitions ensure expertise integration and consolidation in the consultancy sector, allowing them to meet the rising requirements for HEOR services and expand their service portfolios, while fueling innovation, thus providing lucrative growth opportunities for the market.

North America Holds Major Market Share

The high adoption rate of evidence-based reimbursement models, a strong pharmaceutical industry, and easy availability and acceptance of advanced technologies support the market’s growth in North America. The market is expected to witness significant growth in the United States due to the country’s increasing emphasis on outcome-based contracts, strong cost-containment policies, and high drug approvals. Additionally, the strong presence of CROs (contract research organizations and biopharmaceutical companies) and biopharmaceutical companies is further accelerating the demand for HEOR services in both commercial and clinical applications. Additionally, different government policies to bolster the affordability of different medications are also providing lucrative growth opportunities for the market.

For instance, the Inflation Reduction Act (IRA), signed into law in August 2022, in the United States, introduced new drug pricing reforms and emphasized cost-effectiveness thresholds in Medicare price negotiations, resulting in increased reliance on HEOR services to support the introduction of evidence-based pricing strategies.

Impact of U.S. Tariffs on Global Health Economics and Outcomes Research (HEOR) Services Market

The tariffs are increasing medical supply and device costs, resulting in the limited availability of resources to HEOR services. The increased financial strains could also hinder the ability of research organizations and healthcare systems to invest in comprehensive outcome research, impacting long-term healthcare planning.

Market players may need to develop more adaptable and resilient research methodologies, incorporating diverse analytical techniques and data sources to navigate the evolving healthcare industry. By embracing real-world evidence and digital health technologies, the companies can bolster the effectiveness of HEOR services.

Key Players Landscape and Outlook

The key players of the market are focusing on launching novel technological solutions to expand their customer base by providing cutting-edge solutions to leading pharmaceutical, biotech, and research organizations. For instance, in June 2024, IQVIA Inc. launched One Home for Sites, a new platform that functions as a single dashboard and a single sign-on for key tasks and systems a clinical research site requires to perform across all the clinical trials they are conducting. One Home integrates a wide range of digital tools, data, and services into a unified ecosystem, supporting both decentralized and hybrid clinical trial models. The platform aims to streamline trial operations, enhance patient engagement, and improve data quality by offering real-time insights and seamless stakeholder coordination.